ImmunoGen, Inc.

IMGN | $31.23 0.03% 49M

(0.0% 1d) (0.0% 1m) (652.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 8,315,433,277
http://www.immunogen.com
Sec Filling | Patents | 75 employees

(US) ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.

cancer antibody

add to watch list Paper trade email alert is off

Neogen Corporation

NEOG P | $11.94 -1.65% -1.68% 2.9M

Health Technology

(0.0% 1d) (-22.2% 1m) (-27.0% 1y) (0.0% 2d) (0.0% 3d) (1.1% 7d) (21.28% volume)
Earnings Calendar: 2024-04-09
Market Cap: $ 2,586,296,487
http://www.neogen.com
Sec Filling | Patents | 1764 employees

Neogen Corp. engages in the development, manufacture, and sale of products dedicated to food and animal safety. It operates through the following segments: Food Safety, Animal Safety, and Corporate and Eliminations. The Food Safety segment consists of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens, drug residues, and levels of general sanitation. The Animal Safety segment includes a line of consumable products marketed to veterinarians and animal health product distributors. The Corporate and eliminations segment refers to the corporate assets, including cash and cash equivalents, marketable securities, current and deferred tax accounts, and overhead expenses not allocated to specific business segments. The company was founded on June 30, 1981 and is headquartered in Lansing, MI.

security animals veterinarians food diagnostics nash 3d